1. Home
  2. NFE vs DCTH Comparison

NFE vs DCTH Comparison

Compare NFE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Fortress Energy Inc.

NFE

New Fortress Energy Inc.

HOLD

Current Price

$1.22

Market Cap

324.4M

Sector

Utilities

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.51

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFE
DCTH
Founded
2014
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.4M
350.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
NFE
DCTH
Price
$1.22
$10.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$7.70
$22.60
AVG Volume (30 Days)
9.3M
500.6K
Earning Date
02-27-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$1,768,624,000.00
$79,603,000.00
Revenue This Year
N/A
$131.69
Revenue Next Year
$27.93
$39.22
P/E Ratio
N/A
$308.04
Revenue Growth
N/A
251.54
52 Week Low
$0.98
$8.12
52 Week High
$16.66
$18.23

Technical Indicators

Market Signals
Indicator
NFE
DCTH
Relative Strength Index (RSI) 50.87 63.49
Support Level $1.04 $9.69
Resistance Level $1.30 $10.37
Average True Range (ATR) 0.09 0.34
MACD 0.01 0.03
Stochastic Oscillator 58.33 78.21

Price Performance

Historical Comparison
NFE
DCTH

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: